News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Cannimed Announces Voting Results Of AGM For The Election Of Directors



4/21/2017 6:58:13 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs

SASKATOON, Saskatchewan--(BUSINESS WIRE)--CanniMed Therapeutics Inc. (TSX: CMED) (“CMED” or the “Company”), announces, in accordance with the Toronto Stock Exchange requirements, the voting results from its Annual General Meeting held Wednesday, April 19, 2017 in Saskatoon, Saskatchewan.

A total of 10,687,411 common shares were voted at the meeting by proxy, representing 47.52% of the votes attached to all outstanding shares. Shareholders voted in support of all items of business, including the election of all director nominees as follows:

Director Votes For

Per cent of
Votes For

Votes
Withheld

Per cent of
Votes Withheld

Donald Ching 9,699,491 99.95% 5,200 0.05%
Doug Banzet 10,465,338 99.95% 5,225 0.05%
Rob Duguid 10,465,338 99.95% 5,225 0.05%
Marianne Greer 10,465,563 99.95% 5,000 0.05%
Richard Hoyt 10,465,338 99.95% 5,225 0.05%
John Knowles 10,465,538 99.95% 5,025 0.05%
Dwayne L. Lashyn 10,465,538 99.95% 5,025 0.05%
Bruce F. Mackler 10,465,338 99.95% 2,225 0.05%
Brandon P. Price 9,699,691 99.95% 5,000 0.05%
Brent Zettl 10,459,312 99.89% 11,251 0.11%

The Company also confirmed that shareholders approved the appointment of Deloitte LLP (“Deloitte”)

About CanniMed Therapeutics Inc.

The Company is a Canadian-based, international plant biopharmaceutical company and a leader in the Canadian medical cannabis industry, with 15 years of pharmaceutical cannabis cultivation experience, state-of-the-art, GMP-compliant production process and world class research and development platforms with a wide range of pharmaceutical-grade cannabis products. In addition, the Company has an active plant biotechnology research and product development program focused on the production of plant-based materials for pharmaceutical, agricultural and environmental applications.

CanniMed Ltd., through its subsidiaries, was the first producer to be licensed under the Marihuana for Medical Purposes Regulations, the predecessor to the current Access to Cannabis for Medical Purposes Regulations. It was the sole supplier to Health Canada under the former medical marijuana system for 13 years, and has been producing safe and consistent medical marijuana for thousands of Canadian patients, with no incident of product diversion or recalls.

CanniMed Therapeutics Inc.
Dara Willis, 416-836-9272
media@cannimed.com


Read at BioSpace.com


comments powered by Disqus
Cannimed
 
 
Addiction

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES